China's Sinovac Biotech gets govt approval

[Treyfish]

<TABLE cellSpacing=1 cellPadding=0 width="100%" border=0><TBODY><TR><TD class=Title>China's Sinovac Biotech gets govt approval for more bird flu..</TD></TR><TR class=spacer><TD colSpan=2><SPACER type="block" height="1"></TD></TR><TR><TD>2007/05/10 06:49:43</TD></TR>
<TR><TD>vaccine trials
BEIJING, May 10, 2007 (XFN-ASIA via COMTEX) -- Sinovac Biotech Ltd said China's State Food and Drug Administration has granted it approval to begin the Phase II clinical trial of Panflu, a human use vaccine against the H5N1 bird flu virus.
The vaccine was jointly developed with China's Center for Disease Control, the company said in a statement, adding that two versions of the vaccine have been approved for clinical trials.
"We are developing Panflu to vaccinate humans against H5N1 given the significant concern that it may evolve into a virus capable of human-to-human transmission," said company president and CEO Yin Weidong.
sean.mangieri@xfn.com
MMMM:tiphat:
http://www.amex.com/?href=/newsDetails/CmnNewsDet.jsp?id=XpressFeed_NewsDetails_1178794183784.html</TD></TR></TBODY></TABLE>

 

[Treyfish]

Re: China's Sinovac Biotech gets govt approval

China has independently developed using avian flu vaccine into two clinical trials

http://www.sina.com.cn 2007年05月10日22:56新华网​

Http://www.sina.com.cn at 22:56 on May 10, 2007 Xinhuanet

<!--正文内容开始-->

　​

Xinhuanet, Beijing, May 10 (XNA) China has independently developed the use of avian flu vaccines -- "pop flow influenza vaccine, "and recently by the State Food and Drug Administration approval to begin clinical trials into two.

　　​

According to reports, this allowed to enter clinical study of pandemic influenza vaccines at the two. One is a pandemic influenza virus vaccine, will be the first in Phase I clinical trials of adult study group on the basis of Ib test increase the dose of the vaccine will be extended to age 12 to 70 years, to evaluate different doses of the vaccine in all age groups of clinical tolerability and safety; Another one is a pandemic influenza virus vaccine cracking, will conduct Phase I clinical trials, and further expand the scope of age. three-year-old to 11 year age group. On this basis the same time adult group II clinical study to compare different doses, different immune procedures both the immunogenicity and safety, and ultimately determine the dose of the vaccine and immunization procedures, develop standards for registration.

　　​

Pandemic influenza vaccine" from Beijing Branch-biological products company and the China Center for Disease Control and Prevention jointly developed The. Beijing Branch-Biological Products Limited Zhang Jianping, deputy general manager of three said : "If the two clinical trials to be completed. means available to us with a Avian flu vaccine key core technologies.

。​

At the same time, relevant departments of the state, with the support of our ongoing vaccine production capacity-building, once the influenza protection, to provide timely and effective vaccine to control the spread of influenza.

?​

"

　　。​

People with avian flu vaccine is the State "15" scientific and technological projects and issues of major national research projects. The study, we have established the corresponding technical research and development platform, it not only can be produced using avian flu vaccine to deal with avian flu

。​

Caused by the influenza virus pandemic, but also in the avian flu virus mutates and with the rapid vaccine production, The study reached the advanced international level.:tiphat: http://66.249.91.104/translate_c?hl...sina.com.cn/c/h/2007-05-10/225612958451.shtml

<!--正文内容结束-->

​

<STYLE type=text/css>.mediacontent{margin:15px 25px;font-size:14px;line-height:23px;}.mediacontent p{font-size:14px;line-height:23px;margin:15px 0;}</STYLE>

<!--关于内容的操作开始--><!--发表评论开始-->